HYBIO(SZ:300199)2022-12-07 08:24Business Overview - The main products of Hanyu Pharmaceutical include peptide drug formulations, peptide raw materials, and custom peptide services, with the formulation business being the primary source of revenue [2] - The company acquired Chengji Pharmaceutical this year, adding combination packaging products, medical devices, and solid products to its portfolio [2] Product Development and Impact - The approval and production of Eptifibatide (依替巴肽) are expected to significantly enhance the company's performance, as it is a first-line drug for coronary artery disease treatment [3] - Eptifibatide took 10 years from project initiation to market approval and is recommended by major cardiovascular associations [3] - The company has received FDA certification for its raw material production line, marking a significant milestone in its international strategy [3] Strategic Collaborations - Hanyu Pharmaceutical has established a strategic partnership with Akorn Pharmaceuticals for the development of Acetylcysteine (醋酸格拉替雷), which is progressing smoothly and is expected to positively impact future business performance [3] - The collaboration aims to expand the company's international market presence and enhance brand recognition [3] Innovative Technology - The non-invasive continuous glucose monitoring device, GlucoPred, utilizes multiple technologies to provide real-time glucose data, improving the quality of life for diabetes patients [4] - GlucoPred has received approval for Phase III clinical trials in Norway, with expectations for EU certification by the end of the year [4]